

WHO full public health value proposition (FPHVP) for vaccines

(DRAFT template)

Table of Contents		
1	Executive summary and public health value statement	3
1.1	Public health value statement	3
2	WHO public health value propositions for vaccines in early stage development	4
2.1	Target audiences and use of WHO PHVPs	5
2.2	Criteria for selecting vaccines for PHVPs	5
2.3	Methodology for PHVP development	5
3	The global public health need for the vaccine	6
3.1	Disease description	6
3.2	Current methods of surveillance, diagnosis, prevention and treatment	7
3.3	Key gaps in knowledge or research evidence	8
4	**X** vaccine - a strategic priority for WHO	9
4.1	WHO Preferred Product Characteristics (PPCs)	9
5	Stakeholder analysis and involvement	10
5.1	Key gaps in knowledge or research evidence	10
6	Development of the vaccine	11
6.1	Biology of the vaccine	11
6.2	Technical platforms under consideration	11
6.3	Preclinical development: key issues	11
6.4	Clinical development and regulatory pathway: key issues	11
6.5	Vaccine efficacy: key issues	12
6.6	Vaccine safety; key issues	13
6.7	Implementation: key issues	13
6.8	Key gaps in knowledge or research evidence	14
7	Assessment of the vaccine development pipeline	14
7.1	Pipeline summary	14
7.2	Pathway and timescale to licensure	15
7.3	Benchmarking against other vaccines	15
7.4	Probability of success	16
7.5	Key gaps in knowledge or research evidence	16
8	Estimation of disease burden and transmission	17

8.1	Public health inputs and output for modelling	17
8.2	Transmission modelling	17
8.3	Key gaps in knowledge or research evidence	17
9	Defining the market for the vaccine	18
9.1	Potential market segments	18
9.2	Market validation	18
9.3	Strategic vaccine demand forecast	20
9.4	Key gaps in knowledge or research evidence	21
10	Impact of the vaccine on burden of disease and transmission	22
10.1	Measurement of vaccine benefits	22
10.2	Key gaps in knowledge or research evidence	22
11	Economic analysis of the value of the vaccine	23
11.1	Economic analysis: methodology	23
11.2	Economic analysis: summary of findings	23
11.3	Impact of investment	25
11.4	Estimation of cost effectiveness	27
11.5	Key gaps in knowledge or research evidence	27
12	Financing the development of the vaccine	28
12.1	Likely gaps in funding for development for use in LMICs	28
12.2	Key gaps in knowledge or research evidence	29
13	Conclusions and recommendations	30
13.1	Next steps	30
14	References	31
14.1	Further reading	31
Appendix 1. Abbreviations		32
Appendix 2. Glossary		33
Appendix 3. Overview of the product development process		37
Appendix 4. Draft target product profile (TPP)		38
Appendix 5. Authors, advisors and stakeholders interviewed		39